The Carlat Psychiatry Podcast ProLivRx: A New Approval in Depression
25 snips
Jan 19, 2026 In this discussion, Linda Carpenter, a leading expert in psychiatry and chief of the Mood Disorders Program at Butler Hospital, dives into the groundbreaking ProLivRx device for treating difficult depression. She explains the innovative approach of neuromodulation and how ProLivRx differs from other treatments like TMS. The conversation includes insights on clinical trial results, the user-friendly design for at-home use, and considerations for patient selection. Carpenter also addresses monitoring and safety protocols, making this technology a potential game-changer in mental health care.
AI Snips
Chapters
Transcript
Episode notes
Different Devices, Different Brain Targets
- Flow (tDCS) and ProLivRx are both wearable headband devices but work via different mechanisms and targets.
- Flow stimulates frontal cortex directly while ProLivRx targets occipital and trigeminal sensory nerves to influence deeper circuits.
ProLivRx Targets Sensory Nerves For TRD
- ProLivRx is approved specifically for patients who failed at least one antidepressant.
- It stimulates trigeminal and occipital nerve branches that send impulses into brainstem regions tied to mood regulation.
Strong Single Trial Led To Approval
- The pivotal ProLivRx trial had a large effect size (~0.8) and preserved the blind, boosting credibility.
- FDA granted approval based on a single breakthrough-designated trial due to unmet need in treatment-resistant depression.